The expansion of cancer therapeutics has paved the way for improved cancer-related outcomes. Cardiotoxicity from cancer therapy occurs in a small but significant subset of patients, is often poorly understood, and contributes to adverse outcomes at all stages of cancer treatment. Given the often-idiopathic occurrence of cardiotoxicity, novel strategies are needed for risk-stratification and early identification of cancer patients experiencing cardiotoxicity. Clinical and research tools extending from imaging to blood-based biomarkers and pluripotent stem cells are being explored as methods to study the cardiovascular impact of various cancer treatments. Here we provide an overview of tools currently available for evaluation of cardiotoxicity and highlight novel techniques in development aimed at understanding underlying pathophysiologic mechanisms.

中文翻译：

---

临床和研究工具，用于研究癌症疗法对心血管的影响。

癌症治疗方法的扩展为改善与癌症相关的结果铺平了道路。来自癌症治疗的心脏毒性发生在一小部分但重要的患者子集中，人们对其了解很少，并且在癌症治疗的所有阶段均导致不良后果。考虑到心脏毒性经常是特发性的，因此需要新的策略来进行风险分层和早期识别经历心脏毒性的癌症患者。从成像到基于血液的生物标记物和多能干细胞的临床和研究工具正在被研究，作为研究各种癌症治疗方法对心血管的影响的方法。在这里，我们提供了目前可用于评估心脏毒性的工具的概述，并重点介绍了旨在了解潜在病理生理机制的开发中的新技术。